Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non–muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial
Alternating cystoscopy with XBCM reduced the number of follow-up cystoscopies for high-grade NMIBC without affecting detection of any recurrence. The long-term oncological safety of this strategy needs to be validated over longer follow-up.
Authors
- Knud Fabrin
- Andreas Ernst (ORCID: https://orcid.org/0000-0002-1101-8359)
- Lars Dyrskjøt (ORCID: https://orcid.org/0000-0001-7061-9851)
- Thomas Dreyer (ORCID: https://orcid.org/0000-0002-3970-2961)
- Nessn Azawi (ORCID: https://orcid.org/0000-0001-7519-8654)
- Jørgen Bjerggaard Jensen (ORCID: https://orcid.org/0000-0002-4347-739X)
- Simone Brandt (ORCID: https://orcid.org/0000-0002-8558-6674)
- Juan Luis Vásquez (ORCID: https://orcid.org/0009-0001-8005-3545)
Institutions
- Aalborg University Hospital (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- Zealand University Hospital (DK)
Publication Details
- Journal
- European Urology
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1016/j.eururo.2025.03.018
- Citations
- 23
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 46.15
Funders
- Cepheid